Invasive Candidiasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Invasive Candidiasis Market Outlook
Thelansis’s “Invasive Candidiasis
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Invasive Candidiasis treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Invasive
Candidiasis Overview
Invasive
candidiasis is an infection caused by a type of fungus called Candida is a
serious infection that can affect the blood, heart, brain, eyes, bones, and
other parts of the body. Candida species are frequent colonizers of the human
alimentary tract and skin that have emerged as important nosocomial pathogens,
in tandem with advances in modern medical therapeutics. Risk factors for
invasive candidiasis include exposure to broad-spectrum antibiotics and cancer
chemotherapy, advanced care of premature neonates, major abdominal surgery,
organ transplantation, prolonged stay in an intensive care setting, and
implanted medical devices such as vascular catheters and prosthetic heart
valves, and parenteral feeding. Recent treatment directives have been shaped by
the widespread introduction of echinocandins, highly potent and safe
antifungals, into clinical use, essential changes in drug susceptibility
patterns, and the emergence of known and novel drug-resistant drugs Candida
species. Advances in molecular diagnostics have the potential to guide the
early targeted treatment of high-risk patients.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment